-
Markeder
-
Aksjer
Sustainable finance2025 Euronext ESG Trends ReportLes merA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indekser
Access the white paperInvesting in the future of Europe with innovative indicesLes merThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF-er
The European market place for ETFsEuronext ETF EuropeLes merInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fond
-
Obligasjoner
European Defence BondsGroupe BPCE lists the first bondLes merFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Strukturerte produkter
-
Derivater
Where European Government Bonds Meet the FutureFixed Income derivativesLes merTrade mini bond futures on main European government bonds
-
Råvarer
- Oversikt
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Levering og oppgjør
- Spesifikasjoner og ordninger
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLes merEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Ressurser
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLes merJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
BIOSYNEX
Identification
Listing sponsor / Agent
EUROLAND FINANCE
Symbol
XXXX
ISIN code
FR0011005933
Exchange / Market
Euronext
Handelssted
Paris
Products family
Stocks
Market organization
Alternext
ICB
Medical Supplies
Activity description
Biosynex est spécialisée dans la recherche, le développement et la fabrication de tests de diagnostic rapide sur support membranaire en médecine humaine. Biosynex est à ce jour spécialisée dans 4 domaines:
- Les marqueurs d’urgence (rupture de membranes, protection anti tétanos)
- Les maladies infectieuses (mononucléose infectieuse)
- Les pathologies tropicales (paludisme, maladie de Chagas ….)
- Les maladies auto-immunes (intolérance au gluten, thyroïdites auto-immunes,…)
La société emploie actuellement 15 personnes, dont 5 scientifiques dans le département R&D.
Website address
http://biosynex.nexenservices.com
Issuer website
http://biosynex.nexenservices.com
Operation
IPO date
man 21/03/2011
IPO type
Public offer NYSE Alternext à Paris
IPO type
Initial Public offering
Catégorie
IPO